*Five Years Citation in Google scholar (2016 - 2020) is. 1451*   *    IJPR IS INDEXED IN ELSEVIER EMBASE & EBSCO *       

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence
Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
Modeling L-Name Induced Nitric Oxide Deficiency considering the The Cardio- And Endothelial Protective Effects

Author: PAVEL KOLESNICHENKO, DMITRY V. SHCHEBLYKIN, ALEXEY N. DEMIDENKO, OLESYA V. SHCHEBLYKINA, KONSTANTIN M. REZNIKOV, ALHAMZAH MUHI ALDEEN AZEEZ, MAXIM A. ZHUCHENKO, SERGEY A. DEMCHENKO
Abstract: Introduction: Currently, endothelial dysfunction is considered as a predictor of a number of pathologies, including arterial hypertension, ischemic heart disease, chronic heart failure, and is also a pathogenetic component of organ damage in diabetes, hypoestrogenic and other conditions. The purpose of the study is an experimental study of the cardio and vasoprotective effects of etoxidol under conditions of endothelial dysfunction. Materials and methods: The study was performed on Wistar rats. The pharmacological properties of ethylmethylhydroxypyridine malate (etoxidol) were studied on the model of endothelial dysfunction caused by the blockade of NO synthase on the background of the seven-day administration of L-NAME (25 mg / kg). To evaluate the effect of etoxidol on endothelial function, a calculated index of functional vascular samples — the coefficient of endothelial dysfunction — was used, and the morphological picture of the myocardium (determined the diameter of cardiomyocytes), carotid arteries (intima / media ratio) and adrenal mass was studied. Results: The seven-day administration of L-NAME led to the development of severe endothelial dysfunction. The use of etoxidol in a dose of 50 mg / kg against a background of relatively high blood pressure values reduced QED by 30%, and by 49% when using a dose of 90 mg / kg. With a relatively high diameter of cardiomyocytes in all studied groups receiving L-NAME, a significant (p=0.05) difference with the control was obtained with a dose of 90 mg / kg. When studying the intima / media ratio in the carotid artery, a significant decrease in the ratio to the control was obtained in the group receiving etoxidol at a dose of 90 mg / kg. Conclusion: etoxidol has a pronounced endothelial-, vaso- and cardioprotective activity. The effectiveness of the drug is dose-dependent: the best endothelium and cardioprotective effects are achieved with a dose of 90 mg / kg.
Keyword: ethylmethylhydroxypyridine malate, L-NAME, endothelial dysfunction, cardioprotection.
DOI: https://doi.org/10.31838/ijpr/2019.11.04.0320
Download: Request For Article
 




ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free